---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-007998"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T16:37:38.968640+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Contineum appoints Diego Miralles, M.D. to board of directors

## Summary
- Dr. Miralles appointed as Class II director effective March 14, 2025, term expiring at 2026 annual meeting.
- He previously served as an advisor under an agreement with monthly retainer of up to $16,000 and an option for 5,000 shares at $17.92.
- As a non-employee director, he will receive standard cash and equity compensation including an initial option grant for 29,500 shares.
- Dr. Miralles is not considered independent under Nasdaq listing standards.
- He currently serves as CEO of AZURNA Therapeutics and serves on the board of Artiva Biotherapeutics.

## SEC filing metadata
- accession: 0001437749-25-007998
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774925007998/0001437749-25-007998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774925007998/cont20250304_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-007998
- JSON: https://secwatch.observer/filing/0001437749-25-007998.json
- Plain text: https://secwatch.observer/filing/0001437749-25-007998.txt

## Key facts
- Executive change
  Diego Miralles, M.D. was appointed as Director at Contineum Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On March 14, 2025, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Diego Miralles, M.D. as a member of its Board, effective March 14, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855175/000143774925007998/0001437749-25-007998-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.